Mayne Pharma (ASX:MYX) recorded a rise in commercial momentum for the third quarter of FY26, underpinned by the high-impact launch of its DistributeRx platform.
The Adelaide-based pharmaceutical company revealed that DistributeRx achieved prescription demand 72% ahead of internal forecasts within its first month.
The rollout, alongside double-digit growth in its Women’s Health portfolio—specifically BIJUVA® (up 30%) and NEXTSTELLIS® (up 12%)—has bolstered the company’s market position despite broader economic headwinds.
Financially, Mayne Pharma reported a 1% increase in revenue to $85.2 million compared to the previous corresponding period.
While the company recorded a statutory net loss after tax of $21 million, key underlying metrics showed significant year-on-year improvement.
Underlying EBITDA rose by 57% to a loss of $1.4 million, driven largely by a 43% contribution jump from the dermatology segment.
The most striking figure in the report was the company's cash performance. Adjusted operating cash flow from continuing operations soared by 90% to $28.3 million.
As of March 31, Mayne Pharma maintains a robust liquidity position with $86.7 million in cash and marketable securities.
CEO Aaron Gray noted that the company’s "disintermediation strategy" is now delivering tangible results, aided by favourable regulatory shifts from the FDA regarding hormone therapy labelling.
At the time of reporting, Mayne Pharma’s share price was $2.79.